Sign in

NCT07043816Not yet recruiting

Impact of PharmaTE Trial on Glycemic Control, Diabetes Knowledge, Medication Adherence and Quality of Life in Type 2 Diabetes Patients: A Mixed-Method Study Protocol

Source: ClinicalTrials.gov · Last updated 29 Apr 2026

Brief summary (registry, in English)

The goal of this clinical trial is to find out whether a pharmacist-led tele-educational program (PharmaTE trial) can help people with type 2 diabetes manage their condition better. The main questions this study aims to answer are: 1. Does the PharmaTE trial improve blood sugar control (HbA1c levels)? 2. Does it help patients better understand their condition? 3. Does it increase how well patients follow their medication schedule? 4. Does it improve the quality of life for patients with type 2 diabetes? 5. Is this type of tele-education program feasible and acceptable for patients? Participants will: Be randomly placed into one of two groups: Intervention group: Receive five virtual education sessions with a clinical pharmacist over the phone or via Zoom (each lasting 20-30 minutes), in addition to their usual diabetes care. Control group: Continue receiving standard diabetes care from their healthcare team without the additional pharmacist-led sessions. Complete assessments at the beginning and end of the study. These include: A blood test for HbA1c , Questionnaires on diabetes knowledge, medication adherence, and quality of life Some participants in the intervention group will be invited for interviews after the sessions to share their experiences and opinions about the program. Who can join? Adults aged 18-65 with uncontrolled type 2 diabetes (HbA1c \> 7%), receiving care at Ibrahim Bin Hamad Obaidullah Hospital in Ras Al-Khaimah, who speak Arabic and can provide consent.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
154 (estimated)
First submitted
20 Jun 2025
Start date
1 Sept 2026
Primary completion date
30 Aug 2027
Lead sponsor
Rabia Hussain
NCT number
NCT07043816

What you commit to

  • Study type: Interventional
  • Planned participants: 154
  • From 1 Sept 2026 to the primary completion date, 30 Aug 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Diagnosed with type 1 DM or diagnosed with gestational diabetes
  • Immunocompromised patients, e.g., organ transplants, AIDS, cancer patients, and patients on immunosuppressant therapy

Age

  • Under 18 years old

Other

  • Pregnant ladies
  • Patients admitted to the emergency department
  • Patients with severe hepatic or renal dysfunction
  • Having vision or hearing impairments and psychological problems
  • Patients with no or limited access to either a telephone or mobile phone, as well as those without reliable internet access

Who the study is looking for

  • Patients diagnosed with uncontrolled type 2 diabetes (defined as glycated haemoglobin \[HbA1c\] \>7%) within the previous 12 months
  • Adults (18 to 65 years) of either gender
  • Prescribed at least one antidiabetic medication
  • Have access to either a telephone or a mobile phone
  • Treated in an outpatient facility in IBOH, RAK
  • Arabic-speaking patients
  • Patients who understand study information and are given written informed consent.

Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.